Omeros Corporation reported its financial results for the first quarter of 2025, revealing a net loss of $33.5 million, compared to a net loss of $37.2 million in the same period in 2024. The company experienced a decrease in OMIDRIA royalties, earning $6.7 million on U.S. net sales of $22.3 million, down from $9.4 million in royalties on $31.2 million in sales during the first quarter of 2024. Total operating expenses fell to $35.0 million from $39.0 million in the previous year, attributed mainly to the conclusion of the clinical program for narsoplimab in IgA nephropathy, despite increased costs for the Phase 2 zaltenibart program. As of March 31, 2025, Omeros had $52.4 million in cash and short-term investments, a decline of $37.7 million from December 31, 2024. Interest income decreased to $1.1 million from $3.4 million in the first quarter of 2024 due to less cash and investments available for investment.